RxDoctor Payments Data

Angela Stiles, PA

Pulmonary Disease · Athens, GANPI 1669473245

Payments from drug & device makers

$1,646in general payments, 2019–2025

Across 94 payments — averaging $17.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$529
  • AstraZeneca$323
  • Boehringer Ingelheim$127
  • Insmed, Inc.$121
  • Harmony Biosciences LLC$115
  • Inspire Medical Systems, Inc.$53
  • plus $379 from 13 others

What the payments were for

  • Food & beverage$1,63299%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,646 in reported general payments places this provider in the 25th percentile of 365 pulmonary disease providers in Georgia.

See all pulmonary disease providers in Georgia

Medicare billing

Part B allowed, 2024
$2,303
Medicare patients
47
Services billed
56

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter258$201,572
Breo ElliptaFluticasone/Vilanterol108$52,660
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr41$19,737
SymbicortBudesonide/Formoterol Fumarate59$16,410
EliquisApixaban25$15,789
Breztri AerosphereBudesonide/Glycopyr/Formoterol20$14,901
Spiriva RespimatTiotropium Bromide21$11,799
Advair HfaFluticasone Propion/Salmeterol17$5,892
Albuterol Sulfate HfaAlbuterol Sulfate164$5,645
Arnuity ElliptaFluticasone Furoate19$4,371
Fluticasone-VilanterolFluticasone/Vilanterol11$3,750
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate21$3,300
Fluticasone-SalmeterolFluticasone Propion/Salmeterol15$2,606
Ventolin HfaAlbuterol Sulfate26$2,271
Montelukast Sodium216$1,886

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta$529$278,340426 claims
AstraZenecaSymbicort, Breztri Aerosphere$323$31,31079 claims
PfizerEliquis$15$15,78925 claims
Boehringer IngelheimSpiriva Respimat$127$11,79921 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 365 pulmonary disease providers in Georgia.

Other pulmonary disease in Athens

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →